<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3630">
  <stage>Registered</stage>
  <submitdate>28/08/2012</submitdate>
  <approvaldate>28/08/2012</approvaldate>
  <nctid>NCT01676116</nctid>
  <trial_identification>
    <studytitle>The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy</studytitle>
    <scientifictitle>The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy (DUAL III -GLP-1 Switch)</scientifictitle>
    <utrn />
    <trialacronym>DUAL™ III</trialacronym>
    <secondaryid>2012-000209-63</secondaryid>
    <secondaryid>NN9068-3851</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes</healthcondition>
    <healthcondition>Diabetes Mellitus, Type 2</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - insulin degludec/liraglutide
Treatment: drugs - liraglutide
Treatment: drugs - exenatide

Experimental: Insulin degludec/liraglutide + OADs - 

Active Comparator: Liraglutide or exenatide + OADs - 


Treatment: drugs: insulin degludec/liraglutide
Injected subcutaneously (under the skin) once daily. Dose individually adjusted. Subjects will continue their pre-trial OAD treatment without changing the frequency or dose throughout the trial.

Treatment: drugs: liraglutide
Subjects will continue on their pre-trial treatment of liraglutide (Victoza®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.

Treatment: drugs: exenatide
Subjects will continue on their pre-trial treatment of exenatide (Byetta®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in glycosylated haemoglobin (HbA1c) from baseline (randomisation, Visit 2)</outcome>
      <timepoint>Week 0, week 26</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Responders achieving pre-defined target: HbA1c below 7.0% (53 mmol/mol)</outcome>
      <timepoint>Week 26</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Responders achieving pre-defined target: HbA1c below or equal to 6.5% (48 mmol/mol)</outcome>
      <timepoint>Week 26</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in body weight</outcome>
      <timepoint>Week 0, week 26</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in fasting plasma glucose (FPG)</outcome>
      <timepoint>Week 0, week 26</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of severe or minor hypoglycaemic episodes</outcome>
      <timepoint>After 26 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of adverse events (AEs)</outcome>
      <timepoint>After 26 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in patient reported outcomes (PROs) based on the treatment related impact measure - diabetes (TRIM-D) and diabetes treatment satisfaction questionnaire (DTSQ)</outcome>
      <timepoint>Week 0, week 26</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects with type 2 diabetes mellitus

          -  Glycosylated haemoglobin (HbA1c) 7.0-9.0% (53-75 mmol/mol) (both inclusive)

          -  Treatment with daily GLP-1 receptor agonist at maximum dose according to local label
             (i.e. 1.8 mg once daily (OD) Victoza® (liraglutide) or 10 microgram twice daily (BID)
             Byetta® (exenatide)) or documented maximum tolerated dose (i.e. 1.2 mg OD Victoza®
             (liraglutide) or 5 microgram BID Byetta® (exenatide)) in combination with a stable
             daily dose of metformin (equal to or above 1500 mg or documented maximum tolerated
             dose) for 90 days or more prior to screening visit (Visit 1)

          -  BMI (body mass index) equal to or below 40 kg/m^2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Any use of oral anti-diabetic drugs (OADs) (except for metformin, pioglitazone and
             sulphonylurea) for 90 days or less prior to screening visit (Visit 1)

          -  Use of any drug (except metformin,pioglitazone, sulphonylurea and GLP-1 receptor
             agonist) which in the Investigator's opinion could interfere with the blood glucose
             level (e.g. systemic corticosteroids)

          -  Treatment with any insulin regimen (short term treatment due to intercurrent illness
             including gestational diabetes is allowed at the discretion of the Investigator)

          -  Screening calcitonin equal to or above 50 ng/l

          -  Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine
             neoplasia type 2 (MEN2)

          -  Cardiovascular disorders defined as: congestive heart failure (New York Heart
             Association (NYHA) class III-IV), diagnosis of unstable angina pectoris, cerebral
             stroke and/or myocardial infarction within the past 52 weeks prior to screening visit
             (Visit 1) and/or planned coronary, carotid or peripheral artery revascularisation
             procedures

          -  Proliferative retinopathy requiring acute treatment or maculopathy (macular oedema)
             according to the Investigator's opinion

          -  Subjects with a clinically significant, active (during the past 12 months) disease of
             the gastrointestinal, pulmonary, endocrinological (except for the type 2 diabetes
             mellitus), neurological, genitourinary or haematological system that in the opinion of
             the Investigator may confound the results of the trial or pose additional risk in
             administering trial products

          -  History of chronic pancreatitis or idiopathic acute pancreatitis</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>438</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital>Novo Nordisk Investigational Site - Coffs Harbour</hospital>
    <hospital>Novo Nordisk Investigational Site - Merewether</hospital>
    <hospital>Novo Nordisk Investigational Site - Keswick</hospital>
    <hospital>Novo Nordisk Investigational Site - Box Hill</hospital>
    <hospital>Novo Nordisk Investigational Site - Melbourne</hospital>
    <postcode>2450 - Coffs Harbour</postcode>
    <postcode>2291 - Merewether</postcode>
    <postcode>5035 - Keswick</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3004 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Antibes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Boulogne Billancourt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>LA ROCHELLE cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montigny-les-Metz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Narbonne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nimes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Sète</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Venissieux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Nyíregyhaza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Székesfehérvár</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bratislava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Kosice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Lucenec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Nitra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Presov</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novo Nordisk A/S</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial is conducted in Europe, Oceania and the United States of America (USA).

      The aim of the trial is to investigate the efficacy of insulin degludec/liraglutide in
      controlling glycaemia in adults with type 2 diabetes inadequately controlled on glucagon-like
      peptide-1 (GLP-1) receptor agonist and OAD therapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01676116</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Global Clinical Registry (GCR, 1452)</name>
      <address>Novo Nordisk A/S</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>